Pyxis Oncology Inc. has announced revisions to the patient enrollment participants for its Phase 1 monotherapy clinical trial evaluating micvotabart pelidotin, also referred to as MICVO. This trial, designated as NCT05720117, is a first-in-human, open-label, multicenter study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MICVO in individuals with advanced solid tumors. The study includes two parts: a dose escalation phase and a dose expansion phase. The company has confirmed its previous guidance regarding the estimated number of head and neck squamous cell carcinoma patients to be enrolled in the dose expansion phase of the study, as previously disclosed in its quarterly report. Results from this trial have not yet been presented and are anticipated in the future as the trial progresses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.